Immunosuppressive effect of systemic administration of Lactobacillus rhamnosus KL37C-derived exopolysaccharide on the OVA-specific humoral response

Central-European Journal of Immunology

Volumn 37, Issue 4, 2012, Pages 338-344

  Ciszek Lenda, Marta ^a   Nowak, Bernadeta ^a   Śróttek, Małgorzata ^a   GÓRSKA FRa̧CZEK, Sabina ^b   Gamian, Andrzej ^b   Marcinkiewicz, Janusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Exopolysaccharides; Humoral response; Lactobacillus rhamnosus; LPS; Ovalbumin; Probiotics

Indexed keywords

COLLAGEN ANTIBODY; EXOPOLYSACCHARIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; LIPOPOLYSACCHARIDE; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; BIOFILM; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LACTOBACILLUS RHAMNOSUS; MOUSE; NONHUMAN; PROTEIN PURIFICATION;

EID: 84875143014     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: 10.5114/ceji.2012.32722     Document Type: Article

References (34)

1. Vu B, Chen M, Crawford RJ, Ivanova EP (2009): Bacterial extracellular polysaccharides involved in biofilm formation. Molecules 14: 2535-2554.
2. Takeuchi O, Hoshino K, Kawai T, et al. (1999): Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443-451.
3. Vinderola G, Perdigón G, Duarte J, et al. (2006): Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Cytokine 36: 254-260.
4. Chabot S, Yu H-Lig, De Léséleu L (2001): Exopolysaccharides from Lactobacillus rhamnosus RW-9595M stimulate TNF, IL-6 and IL-12 in human and mouse cultured immunocompe-tent cells and IFN-γ in mouse splenocytes. Lait 81: 683-697.
5. Bleau C, Monges A, Rashidan K, et al. (2010): Intermediate chains of exopolysaccharides from Lactobacillus rhamnosus RW-9595M increase IL-10 production by macrophages. J Appl Microbiol 108: 666-675.
6. Wu MH, Pan TM, Wu YJ, et al. (2010): Exopolysaccharide activities from probiotic bifidobacterium: immunomodulato-ry effects (on J774A.1 macrophages) and antimicrobial properties. Int J Food Microbiol 144: 104-110.
7. Ruas-Madiedo P, Gueimonde M, Margolles A, et al. (2006): Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. J Food Prot 69: 2011-2015.
8. Al-Mathkhury HJ, Ali AS, Ghafil JA (2011): Antagonistic effect of bacteriocin against urinary catheter associated Pseudomonas aeruginosa biofilm. N Am J Med Sci 3: 367-370.
9. Ho/iby N, Bjarnsholt T, Givskov M, et al. (2010): Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35: 322-332.
10. Ciszek-Lenda M, Strus M, Górska-Frczek S, et al. (2011): Strain specific immunostimulatory potential of lactobacilli-derived exopolysaccharides. Centr Eur J Immunol 36: 121-129.
11. Nowak B, Ciszek-Lenda M, Sróttek M, et al. (2012): Lacto-bacillus rhamnosus exopolysaccharide ameliorates arthritis induced by the systemic injection of collagen and lipopolysac-charide in DBA/1 mice. Arch Immunol Ther Exp (Warsz) 60: 211-220.
12. Baharav E, Mor F, Halpern M, Weinberger A (2004): Lacto-bacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr 134: 1964-1969.
13. Sugihara R, Yoshimura M, Mori M, et al. (2000): Prevention of collagen-induced arthritis in DBA/1 mice by oral administration of AZ-9, a bacterial polysaccharide from Klebsiella oxytoca. Immunopharmacology 49: 325-333.
14. Lipiñski T, Jones C, Lemercinier X, et al. (2003): Structural analysis of the Lactobacillus rhamnosus strain KL37C exopolysaccharide. Carbohydr Res 338: 605-609.
15. Rudolph U, Finegold MJ, Rich SS, et al. (1995): Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-defi-cient mice. Nat Genet 10: 143-150.
16. Górska-Frczek S, Sandström C, Kenne L, et al. (2011): Structural studies of the exopolysaccharide consisting of a nonasac-charide repeating unit isolated from Lactobacillus rhamnosus KL37B. Carbohydr Res 346: 2926-2932.
17. Cavallo T, Granholm NA (1990): Lipopolysaccharide from gram-negative bacteria enhances polyclonal B cell activation and exacerbates nephritis in MRL/lpr mice. Clin Exp Immunol 82: 515-521.
18. Wells JM, Rossi O, Meijerink M, van Baarlen P (2011): Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci USA 108 Suppl 1: 4607-4614.
19. Marcinkiewicz J, Ciszek M, Bobek M, et al. (2007): Differential inflammatory mediator response in vitro from murine macrophages to lactobacilli and pathogenic intestinal bacteria. Int J Exp Pathol 88: 155-164.
20. Jeon SG, Kayama H, Ueda Y, et al. (2012): Probiotic Bifi-dobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 8: e1002714.
21. Christensen HR, Fro/kiaer H, Pestka JJ (2002): Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 168: 171-178.
22. Kitazawa H, Yamaguchi T, Fujimoto Y, Itoh T (1993): Comparative activity of B-cell mitogen, a phosphopolysaccharide produced by Lactococcus lactis ssp. cremoris on various lymphocytes. Anim Sci Technol 64: 604-607.
23. Bernardo D, Sánchez B, Al-Hassi HO, et al. (2012): Micro-biota/host crosstalk biomarkers: regulatory response of human intestinal dendritic cells exposed to Lactobacillus extracellular encrypted peptide. PLoS One 7: e36262.
24. Segawa S, Hayashi A, Nakakita Y, et al. (2008): Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates the development of dermatitis and inhibits immunoglobulin E production in atopic dermatitis model NC/Nga mice. Biol Pharm Bull 31: 884-889.
25. Van Overtvelt L, Moussu H, Horiot S, et al. (2010): Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine 28: 2986-2992.
26. Malin M, Suomalainen H, Saxelin M, Isolauri E (1996): Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 40: 137-145.
27. Zhang W, Azevedo MS, Wen K, et al. Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs. Vaccine 26: 3655-3661.
28. Paineau D, Carcano D, Leyer G, et al. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol 53: 107-113.
29. De Vuyst L, Degeest B (1999): Heteropolysaccharides from lactic acid bacteria. FEMS Microbiol Rev 23: 153-177.
30. Górska S, Grycko P, Rybka J, Gamian A (2007): Exopolysac-charides of lactic acid bacteria: structure and biosynthesis. Postepy Hig Med Dosw 61: 805-818.
31. Sugihara R, Oiso Y, Matsumoto Y, Ohmori H (2001): Production of an immunosuppressive polysaccharide, AZ9, in the culture of Klebsiella oxytoca strain TNM3. J Biosci Bioeng 92: 485-487.
32. Finamore A, Roselli M, Britti MS, et al. (2012): Lactobacil-lus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsive-ness in ovalbumin-immunized rats. J Nutr 142: 375-381.
33. Sengül N, Ilk S, Asllm B, et al. (2011): The effect of exopolysaccharide-producing probiotic strains on gut oxida-tive damage in experimental colitis. Dig Dis Sci 56: 707-714.
34. Huibregtse IL, Snoeck V, de Creus A, et al. (2007): Induction of ovalbumin-specific tolerance by oral administration of Lac-tococcus lactis secreting ovalbumin. Gastroenterology 133: 517-528.